Epigenetics and pharmacology

British Journal of Pharmacology

Volumn 172, Issue 11, 2015, Pages 2701-2704

  Stefanska, Barbara ^a   Macewan, David J ^b  

^a PURDUE UNIVERSITY   (United States)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DECITABINE; DNA; MICRORNA; RIBOSOME RNA; TRANSFER RNA; UNTRANSLATED RNA; VORINOSTAT; HISTONE;

ALZHEIMER DISEASE; DISEASE CONTROL; DNA METHYLATION; EPIGENETICS; GENE CONTROL; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC TRANSCRIPTION; HISTONE MODIFICATION; HISTORY OF MEDICINE; HUMAN; MOLECULAR MECHANICS; NEOPLASM; NONHUMAN; NUTRITIONAL STATUS; PHARMACOGENOMICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; ACETYLATION; CPG ISLAND; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PHARMACOLOGY;

ACETYLATION; ALZHEIMER DISEASE; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; EPIGENOMICS; GENE EXPRESSION REGULATION; HISTONES; HUMANS; NEOPLASMS; PHARMACOLOGY; RNA, UNTRANSLATED;

EID: 84929179772     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13136     Document Type: Review

References (16)

1. Cheishvili D, Boureau L, Szyf M, (2015). DNA demethylation and invasive cancer: implications for therapeutics. Br J Pharmacol 172: 2705-2715.
2. He Y, Chevillet JR, Liu G, Kim TK, Wang K, (2015). The effects of microRNA on the absorption, distribution, metabolism and excretion of drugs. Br J Pharmacol 172: 2733-2747.
3. Henagan TM, Stefanska B, Fang Z, Navard AM, Ye J, Lenard NR, et al. (2015). Sodium butyrate epigenetically modulates high fat diet-induced skeletal muscle mitochondrial adaptation, obesity and insulin resistance through nucleosome positioning. Br J Pharmacol 172: 2782-2798.
4. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. (2001). Initial sequencing and analysis of the human genome. Nature 409: 860-921.
5. Lirk P, Fiegl H, Weber NC, Hollmann MW, (2015). Epigenetics in the perioperative period. Br J Pharmacol 172: 2748-2755.
6. MacEwan DJ, (2013). Emerging therapeutic aspects in oncology. Br J Pharmacol 169: 1647-1651.
7. Marks PA, Breslow R, (2007). Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25: 84-90.
8. Remely M, Lovrecic L, de la Garza AL, Migliore L, Peterlin B, Milagro FI, et al. (2015). Therapeutic perspectives of epigenetically active nutrients. Br J Pharmacol 172: 2756-2768.
9. Rodríguez-Paredes M, Esteller M, (2011). Cancer epigenetics reaches mainstream oncology. Nat Med 17: 330-339.
10. Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR, Fiddes JC, et al. (1977). Nucleotide sequence of bacteriophage X174 DNA. Nature 265: 687-695.
11. Scarpa S, Cavallaro RA, D'Anselmi F, Fuso A, (2006). Gene silencing through methylation: an epigenetic intervention on Alzheimer disease. J Alzheimers Dis 9: 407-414.
12. Shukeir N, Stefanska B, Parashar S, Chik F, Arakelian A, Szyf M, et al. (2015). Pharmacological methyl group donors block skeletal metastasis in vitro and in vivo. Br J Pharmacol 172: 2769-2781.
13. Simõ-Riudalbas L, Esteller M, (2015). Targeting the histone orthography of cancer: drugs for writers, erasers and readers. Br J Pharmacol 172: 2716-2732.
14. Skipper M, Eccleston A, Gray N, Heemels T, Le Bot N, Marte B, et al. (2015). Presenting the Epigenome Roadmap. Nature 518: 313-314.
15. Stefanska B, Huang J, Bhattacharyya B, Suderman M, Hallet M, Han ZG, et al. (2011). Definition of the landscape of promoter DNA hypomethylation in liver cancer. Cancer Res 71: 5891-5903.
16. Stefanska B, Karlic H, Varga F, Fabianowska-Majewska K, Haslberger AG, (2012). Epigenetic mechanisms in anti-cancer actions of bioactive food components-the implications in cancer prevention. Br J Pharmacol 167: 279-297.